Oklahoma 2024 2024 Regular Session

Oklahoma Senate Bill SB452 Introduced / Bill

Filed 01/17/2023

                     
 
 
Req. No. 304 	Page 1  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
STATE OF OKLAHOMA 
 
1st Session of the 59th Legislature (2023) 
 
SENATE BILL 452 	By: Standridge 
 
 
 
 
 
AS INTRODUCED 
 
An Act relating to the Uniform Controlled Dangerous 
Substances Act; amending 63 O.S. 2021, Section 2-204, 
as amended by Section 1, Ch apter 70, O.S.L. 2022 (63 
O.S. Supp. 2022, Section 2 -204), which relates to 
Schedule I; including certain chemicals in the list 
of Schedule I substances; and provid ing an effective 
date. 
 
 
 
 
 
BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA: 
SECTION 1.     AMENDATORY     63 O.S. 2021, Section 2 -204, as 
amended by Section 1, Chapter 70, O.S.L. 2022 (63 O.S. Supp. 2022, 
Section 2-204), is amended to read as follows: 
Section 2-204. The controlled substances l isted in this section 
are included in Schedule I and include any material, compound, 
mixture or preparation that contains any quan tity of the following 
hallucinogenic substances, their salts, isomers and salts of 
isomers, unless specifically excepted, when the existence of these 
salts, isomers and salts of isomers is possible within the specific 
chemical designation.   
 
 
Req. No. 304 	Page 2  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
A.  Any of the following opiates including their isomers, 
esters, ethers, salts, and salts of isomers, esters, a nd ethers, 
unless specifically excepted, when the existence of these isomers, 
esters, ethers, and salts is possible within the specific chemical 
designation: 
1.  Acetylmethadol; 
2.  Allylprodine; 
3.  Alphacetylmethadol; 
4.  Alphameprodine; 
5.  Alphamethadol; 
6.  Benzethidine; 
7.  Betacetylmethadol; 
8. Betameprodine; 
9.  Betamethadol; 
10.  Betaprodine; 
11.  Clonitazene; 
12.  Dextromoramide; 
13.  Dextrorphan (except its methyl ether); 
14.  Diampromide; 
15.  Diethylthiambutene; 
16.  Dimenoxadol; 
17.  Dimepheptanol; 
18.  Dimethylthiambutene; 
19.  Dioxaphetyl butyrate;   
 
 
Req. No. 304 	Page 3  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
20.  Dipipanone; 
21.  Ethylmethylthiambutene; 
22.  Etonitazene; 
23.  Etoxeridine; 
24.  Furethidine; 
25.  Hydroxypethidine; 
26.  Isotonitazene; 
26. 27. Ketobemidone; 
27. 28.  Levomoramide; 
28. 29. Levophenacylmorphan; 
29. 30. Metonitazene; 
30. 31. Morpheridine; 
31. 32. Noracymethadol; 
32. 33. Norlevorphanol; 
33. 34. Normethadone; 
34. 35. Norpipanone; 
35. 36. Phenadoxone; 
36. 37. Phenampromide; 
37. 38. Phenomorphan; 
38. 39. Phenoperidine; 
39. 40. Piritramide; 
40. 41. Proheptazine; 
41. 42. Properidine; 
43.  Protonitazene;   
 
 
Req. No. 304 	Page 4  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
42. 44. Racemoramide; or 
43. 45. Trimeperidine. 
B.  Any of the following opium derivatives, their salts, 
isomers, and salts of isomers, unless specificall y excepted, when 
the existence of these salts, isomers, and salts of isomers is 
possible within the specific chemical designation: 
1.  Acetorphine; 
2.  Acetyldihydrocodeine; 
3.  Benzylmorphine; 
4.  Codeine methylbromide; 
5.  Codeine-N-Oxide; 
6.  Cyprenorphine; 
7.  Desomorphine; 
8.  Dihydromorphine; 
9.  Etorphine; 
10.  Heroin; 
11.  Hydromorphinol; 
12.  Methyldesorphine; 
13.  Methylhydromorphine; 
14.  Morphine methylbromide; 
15.  Morphine methylsulfonate; 
16.  Morphine-N-Oxide; 
17.  Myrophine; 
18.  Nicocodeine;   
 
 
Req. No. 304 	Page 5  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
19.  Nicomorphine; 
20.  Normorphine; 
21.  Phoclodine; 
22.  Thebacon; 
23.  N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide 
(Acetyl fentanyl); 
24.  N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butenamide 
(Crotonyl fentanyl); 
25.  N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-
furancarboxamide (Furanyl fentanyl ); 
26.  N-phenyl-1-(2-phenylethyl)-4-piperidinamine (4-ANPP); 
27.  N-(1-phenethylpiperidin-4-yl)-N-
phenylcyclopropanecarboxamide (Cyclopropyl fen tanyl); or 
28.  N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide 
(Butyrl fentanyl). 
C.  Any material, compound, mixture, or preparation wh ich 
contains any quantity of the following hallucinogenic substances, 
their salts, isomers, and salts of isomer s, unless specifically 
excepted, when the existence of these salts, isomers, and salts of 
isomers is possible w ithin the specific chemical design ation: 
1.  Methcathinone; 
2. 3, 4-methylenedioxy amphetamine; 
3.  3, 4-methylenedioxy methamphetamine; 
4.  5-methoxy-3, 4-methylenedioxy amphetamine;   
 
 
Req. No. 304 	Page 6  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
5.  3, 4, 5-trimethoxy amphetamine; 
6.  Bufotenine; 
7.  Diethyltryptamine; 
8.  Dimethyltryptamine; 
9.  4-methyl-2, 5-dimethoxyamphetamine; 
10.  Ibogaine; 
11.  Lysergic acid diethylamide; 
12.  Marijuana; 
13.  Mescaline; 
14.  N-benzylpiperazine; 
15.  N-ethyl-3-piperidyl benzilate; 
16.  N-methyl-3-piperidyl benzilate; 
17.  Psilocybin; 
18.  Psilocyn; 
19.  2, 5 dimethoxyamphetamine; 
20. 4 Bromo-2, 5-dimethoxyamphetamine; 
21.  4 methoxyamphetamine; 
22.  Cyclohexamine; 
23.  Salvia Divinorum; 
24.  Salvinorin A; 
25.  Thiophene Analog of Phencyclidine. Also known as: 1-(1-(2-
thienyl) cyclohexyl) piperidine; 2 -Thienyl Analog of Phencyclidine; 
TPCP, TCP; 
26.  Phencyclidine (PCP);   
 
 
Req. No. 304 	Page 7  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
27.  Pyrrolidine Analog for Phencyclidine .  Also known as 1-(1-
Phenylcyclohexyl) - Pyrrolidine, PCPy, PHP; 
28.  1-(3-trifluoromethylphenyl) piperazine; 
29.  Flunitrazepam; 
30.  B-hydroxy-amphetamine; 
31.  B-ketoamphetamine; 
32.  2,5-dimethoxy-4-nitroamphetamine; 
33.  2,5-dimethoxy-4-bromophenethylamine; 
34.  2,5-dimethoxy-4-chlorophenethylamine; 
35.  2,5-dimethoxy-4-iodoamphetamine; 
36.  2,5-dimethoxy-4-iodophenethylamine; 
37.  2,5-dimethoxy-4-methylphenethylamine; 
38. 2,5-dimethoxy-4-ethylphenethylamine; 
39.  2,5-dimethoxy-4-fluorophenethylamine; 
40.  2,5-dimethoxy-4-nitrophenethylamine; 
41.  2,5-dimethoxy-4-ethylthio-phenethylamine; 
42.  2,5-dimethoxy-4-isopropylthio-phenethylamine; 
43.  2,5-dimethoxy-4-propylthio-phenethylamine; 
44.  2,5-dimethoxy-4-cyclopropylmethylthio -phenethylamine; 
45.  2,5-dimethoxy-4-tert-butylthio-phenethylamine; 
46.  2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine; 
47.  5-methoxy-N, N-dimethyltryptamine; 
48.  N-methyltryptamine; 
49. A-ethyltryptamine;   
 
 
Req. No. 304 	Page 8  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
50.  A-methyltryptamine; 
51.  N, N-diethyltryptamine; 
52.  N, N-diisopropyltryptamine; 
53.  N, N-dipropyltryptamine; 
54.  5-methoxy-a-methyltryptamine; 
55.  4-hydroxy-N, N-diethyltryptamine; 
56.  4-hydroxy-N, N-diisopropyltryptamine; 
57.  5-methoxy-N, N-diisopropyltryptamine; 
58.  4-hydroxy-N-isopropyl-N-methyltryptamine; 
59.  3,4-Methylenedioxymethcathinone (Methylone); 
60.  3,4-Methylenedioxypyrovalerone (MDPV); 
61.  4-Methylmethcathinone (Mephedrone); 
62.  4-methoxymethcathinone; 
63. 4-Fluoromethcathinone; 
64.  3-Fluoromethcathinone; 
65.  1-(8-bromobenzo 1,2-b;4,5-b’ difuran-4-yl)-2-aminopropane; 
66.  2,5-Dimethoxy-4-chloroamphetamine; 
67.  4-Methylethcathinone; 
68.  Pyrovalerone; 
69.  N,N-diallyl-5-methoxytryptamine; 
70. 3,4-Methylenedioxy-N-ethylcathinone (Ethylone); 
71.  B-keto-N-Methylbenzodioxolylbutanamine (Butylon e); 
72.  B-keto-Methylbenzodioxolylpentanamine (Pentylone); 
73.  Alpha-Pyrrolidinopentiophenone;   
 
 
Req. No. 304 	Page 9  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
74.  4-Fluoroamphetamine; 
75.  Pentedrone; 
76.  4’-Methyl-a-pyrrolidinohexaphenone; 
77.  2,5-dimethoxy-4-(n)-propylphenethylamine; 
78.  2,5-dimethoxyphenethylamine; 
79.  1,4-Dibenzylpiperazine; 
80.  N,N-Dimethylamphetamine; 
81.  4-Fluoromethamphetamine; 
82.  4-Chloro-2,5-dimethoxy-N-(2-methoxybenzyl)pheneth ylamine 
(25C-NBOMe); 
83.  4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine 
(25I-NBOMe); 
84.  4-Bromo-2,5-dimethoxy-N-(2-methoxybenzy)phenethylamine 
(25B-NBOMe); 
85.  1-(4-Fluorophenyl)piperazine; 
86.  Methoxetamine; 
87.  3,4-dichloro-N[2-dimethylamino)cyclohexyl]-N-
methylbenzamide; 
88.  N-ethyl hexadrone; 
89.  Isopropyl-U-47700; 
90.  Para-fluorobutyrl fentanyl; 
91.  Fluoro isobutryrl fentanyl; 
92.  3-Hydroxy Phencyclidine (PCP); 
93.  3-methoxy Phencyclidine (PCP) ;   
 
 
Req. No. 304 	Page 10  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
94. Flualprazolam; or 
95.  Flubromazolam. 
D.  Unless specifically excepted or unless listed in a di fferent 
schedule, any material, compound, mixtur e, or preparation which 
contains any quantity of the followi ng substances having stimulant 
or depressant effect on the central nervous system: 
1.  Fenethylline; 
2.  Mecloqualone; 
3.  N-ethylamphetamine; 
4.  Methaqualone; 
5.  Gamma-Hydroxybutyric Acid, also known as GHB, gamma-
hydroxybutyrate, 4-hydroxybutyrate, 4-hydroxybutanoic acid, sodium 
oxybate, and sodium oxy butyrate; 
6.  Gamma-Butyrolactone (GBL) as packaged, marketed, 
manufactured or promoted for human consumption, with the exception 
of legitimate food additive and manufacturing purposes; 
7.  Gamma Hydroxyvalerate (GHV) as packaged, marketed, or 
manufactured for human consumption, with th e exception of legitimate 
food additive and manufacturing purposes ; 
8.  Gamma Valerolactone (GVL) as packaged, mar keted, or 
manufactured for human consumption, with the excep tion of legitimate 
food additive and manufacturing purposes;   
 
 
Req. No. 304 	Page 11  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
9.  1,4 Butanediol (1,4 BD or BDO) as packaged, marketed, 
manufactured, or promoted for human consumption with the exception 
of legitimate manufacturing purposes; or 
10.  N-ethylpentylone. 
E.  1. The following industrial uses of Gamma -Butyrolactone, 
Gamma Hydroxyvalerate, Gam ma Valerolactone, or 1,4 Butanediol are 
excluded from all schedule s of controlled substances under this 
title: 
a. pesticides, 
b. photochemical etching, 
c. electrolytes of small batteries or capacitors, 
d. viscosity modifiers in polyurethane, 
e. surface etching of metal coated plastics, 
f. organic paint disbursements for water soluble inks, 
g. pH regulators in the dyeing of wool and polyamide 
fibers, 
h. foundry chemistry as a c atalyst during curing, 
i. curing agents in many coa ting systems based on 
urethanes and amides, 
j. additives and flavoring agents in food, confection ary, 
and beverage products, 
k. synthetic fiber and clothing production, 
l. tetrahydrofuran production, 
m. gamma butyrolactone production,   
 
 
Req. No. 304 	Page 12  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
n. polybutylene terephthalate resin production, 
o. polyester raw materials for polyurethane elastomers 
and foams, 
p. coating resin raw materi al, and 
q. as an intermediate in the manufacture of other 
chemicals and pharmaceutica ls. 
2.  At the request of any person, the Director may exempt any 
other product containing Gamma-Butyrolactone, Gamma Hydroxyvalerate, 
Gamma Valerolactone, or 1,4 Butanedi ol from being included as a 
Schedule I controlled substance if such product is labele d, 
marketed, manufactured and distributed for legit imate industrial use 
in a manner that reduces or eliminates the likelihood of abuse. 
3.  In making a determination regar ding an industrial product, 
the Director, after notice and hearing, shall consider th e 
following: 
a. the history and current pattern of abuse, 
b. the name and labeling of the product, 
c. the intended manner of distribution, adve rtising and 
promotion of the product, and 
d. other factors as may be relevant to and consistent 
with the public health and safety. 
4.  The hearing shall be held in accordance with the procedures 
of the Administrative Procedures Act.   
 
 
Req. No. 304 	Page 13  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
F.  Any material, compound, mixture, or preparation , whether 
produced directly or indirectly from a substance of vegetable origin 
or independently by means of chemical synthesis, or by a combination 
of extraction and chemical synthesis, that contains any quantity of 
the following substances, or that contai ns any of their salts, 
isomers, and salts of isomers when the existence of these salt s, 
isomers, and salts of isomers is possible within the specific 
chemical designation: 
1.  JWH-004; 
2.  JWH-007; 
3.  JWH-009; 
4.  JWH-015; 
5.  JWH-016; 
6.  JWH-018; 
7.  JWH-019; 
8.  JWH-020; 
9.  JWH-030; 
10.  JWH-046; 
11.  JWH-047; 
12.  JWH-048; 
13.  JWH-049; 
14.  JWH-050; 
15.  JWH-070; 
16.  JWH-071;   
 
 
Req. No. 304 	Page 14  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
17.  JWH-072; 
18.  JWH-073; 
19.  JWH-076; 
20.  JWH-079; 
21.  JWH-080; 
22.  JWH-081; 
23.  JWH-082; 
24.  JWH-094; 
25.  JWH-096; 
26.  JWH-098; 
27.  JWH-116; 
28.  JWH-120; 
29.  JWH-122; 
30.  JWH-145; 
31.  JWH-146; 
32.  JWH-147; 
33.  JWH-148; 
34.  JWH-149; 
35. JWH-150; 
36.  JWH-156; 
37.  JWH-167; 
38.  JWH-175; 
39. JWH-180; 
40.  JWH-181;   
 
 
Req. No. 304 	Page 15  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
41.  JWH-182; 
42.  JWH-184; 
43.  JWH-185; 
44. JWH-189; 
45.  JWH-192; 
46.  JWH-193; 
47.  JWH-194; 
48.  JWH-195; 
49.  JWH-196; 
50.  JWH-197; 
51.  JWH-198; 
52.  JWH-199; 
53.  JWH-200; 
54.  JWH-201; 
55.  JWH-202; 
56.  JWH-203; 
57. JWH-204; 
58.  JWH-205; 
59.  JWH-206; 
60.  JWH-207; 
61.  JWH-208; 
62.  JWH-209; 
63.  JWH-210; 
64.  JWH-211;   
 
 
Req. No. 304 	Page 16  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
65.  JWH-212; 
66.  JWH-213; 
67.  JWH-234; 
68.  JWH-235; 
69. JWH-236; 
70.  JWH-237; 
71.  JWH-239; 
72. JWH-240; 
73.  JWH-241; 
74.  JWH-242; 
75.  JWH-243; 
76.  JWH-244; 
77.  JWH-245; 
78.  JWH-246; 
79.  JWH-248; 
80.  JWH-249; 
81.  JWH-250; 
82.  JWH-251; 
83.  JWH-252; 
84.  JWH-253; 
85.  JWH-262; 
86.  JWH-292; 
87.  JWH-293; 
88.  JWH-302;   
 
 
Req. No. 304 	Page 17  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
89.  JWH-303; 
90.  JWH-304; 
91.  JWH-305; 
92.  JWH-306; 
93.  JWH-307; 
94.  JWH-308; 
95.  JWH-311; 
96.  JWH-312; 
97.  JWH-313; 
98.  JWH-314; 
99.  JWH-315; 
100.  JWH-316; 
101.  JWH-346; 
102.  JWH-348; 
103. JWH-363; 
104.  JWH-364; 
105.  JWH-365; 
106.  JWH-367; 
107.  JWH-368; 
108.  JWH-369; 
109.  JWH-370; 
110. JWH-371; 
111. JWH-373; 
112.  JWH-386;   
 
 
Req. No. 304 	Page 18  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
113.  JWH-387; 
114.  JWH-392; 
115.  JWH-394; 
116.  JWH-395; 
117.  JWH-397; 
118.  JWH-398; 
119. JWH-399; 
120.  JWH-400; 
121.  JWH-412; 
122.  JWH-413; 
123.  JWH-414; 
124.  JWH-415; 
125. CP-55, 940; 
126.  CP-47, 497; 
127.  HU-210; 
128.  HU-211; 
129.  WIN-55, 212-2; 
130.  AM-2201; 
131.  AM-2233; 
132.  JWH-018 adamantyl-carboxamide; 
133. AKB48; 
134.  JWH-122 N-(4-pentenyl)analog; 
135.  MAM2201; 
136.  URB597;   
 
 
Req. No. 304 	Page 19  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
137.  URB602; 
138.  URB754; 
139.  UR144; 
140.  XLR11; 
141.  A-796,260; 
142.  STS-135; 
143.  AB-FUBINACA; 
144.  AB-PINACA; 
145.  PB-22; 
146.  AKB48 N-5-Fluorpentyl; 
147. AM1248; 
148.  FUB-PB-22; 
149.  ADB-FUBINACA; 
150.  BB-22; 
151.  5-Fluoro PB-22; or 
152.  5-Fluoro AKB-48. 
G.  In addition to those substances liste d in subsection F of 
this section, unless specifically excepted or unless listed in 
another schedule, any material, compound, mixture, or preparation 
which contains any quantity of a synthetic cannabinoid found to be 
in any of the following chemical groups : 
1.  Naphthoylindoles: any compound containing a 3 -(1-
naphthoyl)indole structure with or without substitution at the 
nitrogen atom of the indole ring by an alk yl, haloalkyl, cyanoalkyl,   
 
 
Req. No. 304 	Page 20  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
alkenyl, cycloalkylmethyl, cycloalkyle thyl, benzyl, halobenzyl, 1 -
(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1 -(N-methyl-
2-pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl, 
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or 
halophenyl group, whether or not further su bstituted on the indole 
ring to any extent, and whether or not substituted on the naphthyl 
ring to any extent.  Naphthoylindoles include, but are not limited 
to: 
a. 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-
200), 
b. 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201), 
c. 1-pentyl-3-(1-naphthoyl)indole (JWH-018), 
d. 1-butyl-3-(1-naphthoyl)indole (JWH-073), 
e. 1-pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081), 
f. 1-propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015), 
g. 1-hexyl-3-(1-naphthoyl)indole (JWH-019), 
h. 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122), 
i. 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210), 
j. 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398), 
k. 1-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH-007), 
l. 1-pentyl-3-(7-methoxy-1-naphthoyl)indole (JWH-164), 
m. 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole 
(JWH-098), 
n. 1-pentyl-3-(4-fluoro-1-naphthoyl)indole (JWH-412),   
 
 
Req. No. 304 	Page 21  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
o. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(1-
naphthoyl)indole (AM-1220), 
p. 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole 
(MAM-2201), or 
q. 1-(4-cyanobutyl)-3-(1-naphthoyl)indole (AM-2232); 
2.  Naphthylmethylindoles: any compound containing a 1H-indol-3-
yl-(1-naphthyl)methane structu re with or without substitution at the 
nitrogen atom of the indole ring by an alkyl , haloalkyl, cyanoalkyl, 
alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -
(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, 
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or 
halophenyl group, whether or not further substituted on the indole 
ring to any extent, and whether or not substituted on the naphthyl 
ring to any extent. Naphthylmethylindoles include, but are not 
limited to, (1-pentylindol-3-yl)(1-naphthyl)methane (JWH-175); 
3.  Naphthoylpyrroles: any compound containing a 3-(1-
naphthoyl)pyrrole structure with or without substitution at the 
nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, 
cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 
halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, 
phenyl, or halophenyl group, whether or not further substitu ted on   
 
 
Req. No. 304 	Page 22  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
the pyrrole ring to any extent, and whether or not substituted on 
the naphthyl group to an y extent.  Naphthoylpyrroles include, but 
are not limited to: 
a. 1-hexyl-2-phenyl-4-(1-naphthoyl)pyrrole (J WH-147), 
b. 1-pentyl-5-(2-methylphenyl)-3-(1-naphthoyl)pyrrole 
(JWH-370), 
c. 1-pentyl-3-(1-naphthoyl)pyrrole (JWH-030), or 
d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole (JWH-147); 
4.  Naphthylideneindenes: any compound con taining a 1-(1-
naphthylmethylene)indene structure with or without substitution at 
the 3-position of the indene ring by a n alkyl, haloalkyl, 
cyanoalkyl, alkenyl, cycloalkylmethyl, cycloal kylethyl, benzyl, 
halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
morpholinyl)methyl, (t etrahydropyran-4-yl)methyl, 1-methylazepanyl, 
phenyl, or halophenyl group, whether or not further substituted on 
the indene group to any extent, and whether or not sub stituted on 
the naphthyl group to any extent.  Naphthylmethylindenes include, 
but are not limited to, (1-[(3-pentyl)-1H-inden-1-
ylidene)methyl]naphthalene (JWH-176); 
5.  Phenylacetylindoles: any compound containing a 3-
phenylacetylindole structure with or without substitution at the 
nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoal kyl, 
alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-  
 
 
Req. No. 304 	Page 23  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, 
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or 
halophenyl group, whether or no t further substituted on the indole 
ring to any extent, and whethe r or not substituted on the phenyl 
ring to any extent.  Phenylacetylindoles include, but are not 
limited to: 
a. 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH -250), 
b. 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole 
(RCS-8), 
c. 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203), 
d. 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251), 
e. 1-pentyl-3-(4-methoxyphenylacetyl)indole (JWH-201), or 
f. 1-pentyl-3-(3-methoxyphenylacetyl)indole (JWH -302); 
6.  Cyclohexylphenols: any compound containing a 2 -(3-
hydroxycyclohexyl)phenol struc ture with or without subs titution at 
the 5-position of the phenolic ring by an alkyl, haloalkyl, 
cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 
halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
morpholinyl)ethyl, 1 -(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- 
morpholinyl)methyl, (tetrahydropyran -4-yl)methyl, 1-methylazepanyl, 
phenyl, or halophenyl group, and whether or not further substituted 
on the cyclohexyl ring to any extent. Cyclohexylphenols include, 
but are not limited to:   
 
 
Req. No. 304 	Page 24  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
a. 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-
hydroxycyclohexyl]-phenol (CP-47,497), 
b. 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-
phenol (cannabicyclohexanol; CP -47,497 C8 homologue), 
or 
c. 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-
hydroxypropyl)cyclohexyl]-phenol (CP 55, 940); 
7.  Benzoylindoles: any compound conta ining a 3-(benzoyl)indole 
structure with or without substitution at the nitrogen atom of the 
indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, 
cycloalkylmethyl, cycloalkylethyl, ben zyl, halobenzyl, 1-(N-methyl-
2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, 
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or 
halophenyl group, whether o r not further substituted on the indole 
ring to any extent, and whether or not substituted on the phenyl 
group to any extent.  Benzoylindoles include, but are no t limited 
to: 
a. 1-pentyl-3-(4-methoxybenzoyl)indole (RCS-4), 
b. 1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4-
methoxybenzoyl)indole (Pravadoline or W IN 48, 098), 
c. 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole ( AM-694), 
d. 1-pentyl-3-(2-iodobenzoyl)indole (AM -679), or   
 
 
Req. No. 304 	Page 25  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
e. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(2-
iodobenzoyl)indole (AM-2233); 
8.  Cyclopropoylindoles: Any compound containing a 3-
(cyclopropoyl)indole structure with substitutio n at the nitrogen 
atom of the indole ring by an alkyl, haloalkyl, cyanoalk yl, alkenyl, 
cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-
2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, 
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or 
halophenyl group, whether or not further substituted in the indole 
ring to any extent and whether or not substituted in t he 
cyclopropoyl ring to a ny extent.  Cyclopropoylindoles inclu de, but 
are not limited to: 
a. 1-pentyl-3-(2,2,3,3-tetramethylcyclopropoyl )indole 
(UR-144), 
b. 1-(5-chloropentyl)-3-(2,2,3,3-
tetramethylcyclopropoyl)indole (5Cl -UR-144), or 
c. 1-(5-fluoropentyl)-3-(2,2,3,3-
tetramethylcyclopropoyl)indole (XLR11); 
9.  Indole Amides:  Any compound containing a 1H-Indole-3-
carboxamide structure with or without substitution at the nitrogen 
atom of the indole ring by an alkyl, haloalk yl, cyanoalkyl, alkenyl, 
cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -(N-methyl-
2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1-(N-methyl-2-  
 
 
Req. No. 304 	Page 26  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, 
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or 
halophenyl group, whethe r or not substituted at t he carboxamide 
group by an adamantyl, naphthyl, phenyl, benz yl, quinolinyl, 
cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not 
further substituted in the indole, adamantyl , naphthyl, phenyl, 
pyrrole, quninolinyl, or cycloa lkyl rings to any extent .  Indole 
Amides include, but are not limited to: 
a. N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide 
(2NE1), 
b. N-(1-adamantyl)-1-(5-fluoropentyl-1H-indole-3-
carboxamide (STS-135), 
c. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
indole-3-carboxamide (ADBICA), 
d. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-
fluoropentyl)-1H-indole-3-carboxamide (5F-ADBICA), 
e. N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide 
(NNE1), 
f. 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-
carboxamide (5F-NNE1), 
g. N-benzyl-1-pentyl-1H-indole-3-carboxamide (SDB-006), 
or   
 
 
Req. No. 304 	Page 27  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
h. N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide 
(5F-SDB-006); 
10.  Indole Esters:  Any compound containing a 1H -Indole-3-
carboxylate structure with or without substitu tion at the nitrogen 
atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, 
cycloalkylmethyl, cycloalkylet hyl, benzyl, halobenzyl, 1-(N-methyl-
2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1 -(N-methyl-2-
pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl, 
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or 
halophenyl group, whet her or not substituted at the carboxylate 
group by an adamantyl, naphthy l, phenyl, benzyl, quinolinyl, 
cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not 
further substituted in the in dole, adamantyl, naphthyl, phenyl, 
pyrrole, quinolinyl, or cycloalkyl rings to any exte nt.  Indole 
Esters include, but are not limited to: 
a. quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-
22), 
b. quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-
carboxylate (5F-PB-22), 
c. quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-
carboxylate (BB-22),   
 
 
Req. No. 304 	Page 28  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
d. naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-
carboxylate (FDU-PB-22), or 
e. naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
carboxylate (NM2201); 
11.  Adamantanoylindoles:  Any compound containing an 
adamantanyl-(1H-indol-3-yl)methanone structure with or without 
substitution at the ni trogen atom of the indole ring by an alkyl, 
haloalkyl, cyanoalkyl, alkenyl, cycloalkylmet hyl, cycloalkylethyl, 
benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2 -(4-
morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3- 
morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, 
phenyl, or halophenyl group, whether o r not further substituted in 
the indole ring to any extent and whether or not substit uted in the 
adamantyl ring to any extent .  Adamantanoylindoles include, but are 
not limited to: 
a. adamantan-1-yl[1-[(1-methyl-2-piperidinyl)methyl]-1H-
indol-3-yl]methanone (AM1248), or 
b. adamantan-1-yl-(1-pentyl-1H-indol-3-yl)methanone (AB-
001); 
12.  Carbazole Ketone: Any compound containing (9H -carbazole-3-
yl) methanone structure wi th or without substitution at the nitrogen 
atom of the carbazole r ing by an alkyl, haloal kyl, cyanoalkyl, 
alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -
(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-  
 
 
Req. No. 304 	Page 29  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, 
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or 
halophenyl group, with substitution at the carbon of the methanone 
group by an adamantyl, naphthyl, phenyl, benzyl, quinoliny l, 
cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not 
further substituted at the carbazole, adamantyl, naphthyl , phenyl, 
pyrrole, quinolinyl, or cycloalkyl rings to any extent.  Carbazole 
Ketones include, but are not limited to, na phthalen-1-yl(9-pentyl-
9H-carbazol-3-yl)methanone (EG-018); 
13.  Benzimidazole Ketone :  Any compound containing 
(benzimidazole-2-yl) methanone structure with or withou t 
substitution at either nitrogen atom of the benzimidazole ring b y an 
alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, 
cycloalkylethyl, benzyl, halobenzyl, 1 -(N-methyl-2-
piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1 -(N-methyl-2-
pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, 
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, pheny l, or 
halophenyl group, with substitution at the carbon of the methanone 
group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, 
cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not   
 
 
Req. No. 304 	Page 30  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
further substituted in the benzimidazole, adamantyl, naphthyl, 
phenyl, pyrrole, quinolinyl, o r cycloalkyl rings to any extent.  
Benzimidazole Ketones include, but are not limited to: 
a. naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2-
l)methanone (JWH-018 benzimidazole analog), or 
b. (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-
yl)(naphthalen-1-yl)methanone (FUBIMINA); and 
14.  Modified by Replacement:  any compound defined in this 
subsection that is modified by r eplacement of a carbon with nitrogen 
in the indole, naphthyl , indene, benzimidazole, or carbazole ring. 
H.  Any prescription drug approved by the federal Food and Drug 
Administration under the pr ovisions of Section 505 of the Federal 
Food, Drug and Cosmeti c Act, Title 21 of the United States Code, 
Section 355, that is designated, rescheduled or del eted as a 
controlled substance under federal law by the United States Drug 
Enforcement Administration shall be exc luded from Schedule I a nd 
shall be prescribed, d istributed, dispensed or used in accordance 
with federal law upon the issuance of a notice, final rule or 
interim final rule by the United Sta tes Drug Enforcement 
Administration designating, rescheduling or deleting as a controlled 
substance such a drug pr oduct under federal law, unless and until 
the Board of Pharmacy takes action pursuant to Section 2 -201 of this 
title.  If the Board of Pharmac y does not take action pursuant to 
Section 2-201 of this title, the drug product shall be deemed to be   
 
 
Req. No. 304 	Page 31  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
   1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
designated, rescheduled or deleted as a controlled substance in 
accordance with federal law and in compliance with the Uniform 
Controlled Dangerous Subst ances Act. 
SECTION 2.  This act shall become effective November 1, 2023. 
 
59-1-304 JES 1/17/2023 10:15:30 AM